U

Universitätsklinikum Essen | Innere Klinik(Tumorforschung) - Westdeutsches Tumorzentrum

Research site
(Unclaimed)
Location
WTZ-Ambulanz, 2. OG. Raum 2.61 Hufelandstr. 55, Essen, North Rhine-Westphalia, Germany
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

58 of 261
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
"InDACtion" vs "3+7" Induction in AML

Older patients with acute myeloid leukemia (AML) have a small (< 10%) chance of long-term survival. Despite the treatment of elderly AML patients wit...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: decitabine
Drug: standard combination chemotherapy

This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety a...

Enrolling
Multifocal Motor Neuropathy (MMN)
Biological: ARGX-117
Other: Placebo

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: sotorasib
Drug: Anti PD-1/L1

The primary objective of this study is:• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia...

Invitation-only
Warm Antibody Autoimmune Hemolytic Anemia
Drug: Fostamatinib disodium

The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and o...

Active, not recruiting
Follicular Lymphoma
Drug: Obinutuzumab
Drug: Copanlisib
Locations recently updated

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Polatuzumab vedotin Placebo
Drug: Vincristine Placebo
Locations recently updated

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in s...

Enrolling
Sickle Cell Disease
Other: Mitapivat-matching placebo
Drug: Mitapivat

The primary purpose of this study is to compare the effect of mitapivat versus placebo on anemia in participants with alpha- or beta-non-transfusion...

Active, not recruiting
Non-Transfusion-dependent Alpha-Thalassemia
Non-Transfusion-dependent Beta-Thalassemia
Drug: Placebo Matching Mitapivat
Drug: Mitapivat

The primary purpose of this study is to compare the effect of mitapivat versus placebo on transfusion burden in participants with transfusion-depende...

Active, not recruiting
Transfusion-dependent Alpha-Thalassemia
Transfusion-dependent Beta-Thalassemia
Drug: Placebo Matching Mitapivat
Drug: Mitapivat

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally...

Enrolling
Breast Cancer
Drug: Bevacizumab
Drug: Capecitabine

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat...

Enrolling
Migraine
Medication Overuse Headache
Drug: Placebo
Drug: Eptinezumab

Researchers are looking for a better way to help people with known or suspected brain or spinal cord-related problems scheduled for a "contrast-enhan...

Enrolling
Central Nervous System Pathology
Contrast Enhancement in Magnetic Resonance Imaging
Drug: Gadobutrol
Drug: Gadoquatrane (BAY1747846)

This study will be comprised of 2 parts: Part 1 (dose escalation) will be conducted to evaluate the safety and tolerability of 2 doses (100 milligram...

Active, not recruiting
Muscular Dystrophy, Duchenne
Drug: Eteplirsen

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria,...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Finerenone (Kerendia, BAY94-8862)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria,...

Enrolling
Chronic Kidney Disease
Proteinuria
Drug: Placebo
Drug: Finerenone (Kerendia, BAY94-8862)

This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle...

Enrolling
ACUTE LYMPHOBLASTIC LEUKEMIA
Drug: Inotuzumab ozogamicin
Drug: ALLR3

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a p...

Active, not recruiting
Solid Tumors Harboring NTRK Fusion
Drug: BAY2757556 (Larotrectinib, Vitrakvi)

The purpose of this clinical phase 3 randomized trial is to compare two different dosing schedules of Docetaxel in combination with ADT and Darolutam...

Enrolling
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Drug: Docetaxel
Drug: Standard ADT (androgen deprivation therapy)

The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-d...

Active, not recruiting
Gastro-enteropancreatic Neuroendocrine Tumor
Drug: Lanreotide ATG
Drug: CAM2029

Trial conditions

Leukemia (17 trials)
Carcinoma (10 trials)
Melanoma (10 trials)
Ovarian Cancer (9 trials)
Recurrence (9 trials)
Acute Myeloid Leukemia (8 trials)
Breast Cancer (8 trials)
Fibrosis (8 trials)
Precursor Cell Lymphobla... (8 trials)
Heart Failure (7 trials)

And 90 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems